DTC Genomics Targeted by Congressional Investigation
May 20, 2010
DTC Genomics Targeted by Congressional Investigation
Henry Waxman, chairman of the House Committee on Energy and Commerce, said that the committee is investigating direct-to-consumer genomic companies and has sent letters to three firms — Pathway Genomics, 23andMe, and Navigenics.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- As Congress Investigates DTC Genomics Market, Firms Vow Cooperation
May 26, 2010 / Pharmacogenomics Reporter - DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access
March 16, 2011 / Pharmacogenomics Reporter - In Wake of 'Flawed' GAO Report, Consumer Genomics Firms Call for Regulatory Plan for DTC Industry
July 28, 2010 / Pharmacogenomics Reporter - FDA Tells Congress it is Mulling Strategies to Regulate DTC Genetic Tests as Medical Devices
July 28, 2010 / Pharmacogenomics Reporter - Seeking 510(k) Clearance for Genomic Testing Service, 23andMe Maintains Direct-to-Consumer Ethos
August 1, 2012 / Pharmacogenomics Reporter